White House to push ibogaine research for PTSD, depression treatment

The White House is preparing to direct federal agencies to reconsider restrictions on ibogaine, a naturally occurring psychedelic compound derived from a shrub native to Africa, in a move that would push research on PTSD, depression and other mental-health conditions without immediately legalizing it for medical use. The drug would remain a Schedule I substance, underscoring how cautiously the administration is moving even as it signals new openness to psychedelic therapy.

The executive order is expected to arrive as soon as this week and would focus on accelerating study rather than reclassifying ibogaine. That distinction matters. A White House directive can tell agencies to revisit barriers, review approvals and open the door to more federally supported research, but it cannot by itself turn the drug into an approved treatment or erase the safety questions that have kept it tightly controlled.

Interest in ibogaine has grown among veterans and researchers who say current care leaves too many people behind, especially those living with post-traumatic stress, traumatic brain injury, depression and addiction. Stanford Medicine published findings in January 2024 showing that ibogaine, paired with magnesium to protect the heart, reduced PTSD, anxiety and depression while improving functioning in veterans with TBI. The study involved 30 male Special Operations Forces veterans. The accompanying Nature Medicine paper also warned that ibogaine has been associated with fatal cardiac arrhythmia risk.

The push comes after the Department of Veterans Affairs expanded its own psychedelic-related research. In December 2024, the VA announced its first study of MDMA-assisted therapy for PTSD and alcohol use disorder among veterans, and later reports said psychedelic-assisted therapy trials had been expanded at nine facilities. That work has unfolded as federal regulators have remained cautious. In April 2026, the Food and Drug Administration issued a complete response letter rejecting Lykos Therapeutics’ MDMA-assisted PTSD application and requested more clinical trials.

The political stakes are growing as well. Senators Ruben Gallego and David McCormick introduced bipartisan legislation in March 2026 to increase federally funded research on innovative therapies for veterans with PTSD, substance use disorder and depression. Supporters say those efforts reflect a practical response to unmet need. Critics, including safety-focused researchers, warn that the federal government must move carefully given the heart risks and the still-limited evidence base. The White House is betting that research can advance faster than regulation, but the treatment path for ibogaine remains years from a routine medical option.